biocryst is terminating bcx5191 program, page-21

Biota Holders,
How about an economic cost/benefit analysis of the benficiaries from use of Relenza in treating influenza:

1 Government (& Health Care Funds)
- reduced time off work - increased productivity
- reduced hospitalisation - emergency dept visits
- reduced critical care unit costs (I/V Relenza)
- reduced long term impact on some individuals health
- reduced deaths (and loss of long term productivity)
- reduced spread of infection
- reduced infant deaths (I/V Relenza)
- resistance issues with Tamiflu
- low cost - about $50 per course (less for governments)
- long life product - doesnt require refrigeration
- easily dispensed (inhalation), straight to site of activity in lungs
- non-toxic, well tolerated,rapid acting
- reduced stillbirths in pregnant women
- reduced impact on schools, sporting events, retirement villages & nursing homes
- reduced emergency disease control responses
- reduced risk to armed forces
- improved preparation for a Pandemic
- 6 month delay in producing vaccine against new influenza strains (too late)
- Relenza active against all strains of influenza
- seasonal influenza outbreaks annual usually in winter in Northern and Southern Hemispheres, pandemics every 10-25 years.


2 Private individual - all of the above plus
- reduced duration illness
- reduced impact on business
- reduced impact on leisure activities including costly holidays
- low cost insurance policy re long term impact, hospitalisation & potentially death
- reduced risk to pregnant women
- reduced risk to children and elderly

Where is the publicity, publications, lobbying on the economic benefits?

Regards
Kangaroo1